Adaptimmune stock plunges after announcing Nasdaq delisting plans
MIAMI - Longeveron Inc. (NASDAQ:LGVN), a biotechnology company with a current market capitalization of $15.7 million, announced Wednesday the appointment of George Paletta, Jr., MD, MBA, to its Board of Directors. Dr. Paletta serves as the head team doctor for the St. Louis Cardinals and brings experience as an orthopedic surgeon, inventor, and entrepreneur. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 3.4x, though it faces significant cash burn challenges.
Dr. Paletta has previously developed ambulatory surgical centers and participated in deals totaling nearly $1 billion. He holds multiple patents in both orthopedic and cardiovascular fields and has invested in various early-stage ventures across different industries. While the stock has experienced a significant decline of 50% over the past six months, InvestingPro analysis suggests the company is currently trading below its Fair Value, with 8 additional key insights available for subscribers.
"I am excited to join the Longeveron Board at this transformational period for the Company," said Dr. Paletta in the press release statement. "As a physician, I see tremendous potential for stem cell therapy to bring new treatment options to patients suffering from rare pediatric and chronic aging-related conditions." The company’s financial position shows more cash than debt on its balance sheet, though it reported an EBITDA of -$18.4 million in the last twelve months.
Longeveron is advancing laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy isolated from bone marrow of young adult donors. The company’s lead program for hypoplastic left heart syndrome (HLHS) has completed enrollment in a pivotal clinical trial with data expected in 2026. Detailed financial analysis and comprehensive research reports for LGVN are available through InvestingPro, helping investors make informed decisions about this developing biotech company.
The biotechnology company is pursuing four clinical indications: HLHS, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy, and Aging-related Frailty. Its development programs have received multiple FDA designations, including Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy designations.
Dr. Paletta received his medical degree from Johns Hopkins University School of Medicine and completed his orthopedic residency at Hospital for Special Surgery in New York City. He later earned an MBA from Washington University’s Olin School of Business.
In other recent news, Longeveron Inc. reported its Q2 2025 earnings, revealing a 31% decline in revenue to $700,000 for the first half of the year. The company also experienced a net loss of approximately $10 million. Despite these financial challenges, the market responded positively, which may be attributed to strategic advancements and product developments. Additionally, Longeveron announced a leadership reorganization, appointing Than Powell as interim Chief Executive Officer. Powell replaces Wa’el Hashad, who has stepped down to pursue other opportunities. Dr. Joshua Hare, co-founder and Chief Science Officer, has been named Executive Chairman of the Board. These developments reflect Longeveron’s ongoing efforts to navigate its current challenges and position itself for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.